Weekly Wrap - July 31, 2026

In this week's HealthCap Weekly Wrap, we explore several developments shaping senior care today. We begin with the FDA approval of Awiqli, the first once-weekly basal insulin for adults with Type 2 diabetes, and discuss what it could mean for medication adherence, glucose monitoring, and diabetes management in senior care communities. We also examine the FDA's new Adverse Event Monitoring System, a unified platform designed to improve transparency and provide easier access to safety data across drugs, vaccines, medical devices, and other regulated products. The episode continues with insights from the 2026 Tardive Dyskinesia Toolkit, highlighting the importance of early recognition and routine screening, as well as a Mather Institute report that explores the psychological, social, and physical barriers that often prevent older adults from participating in regular physical activity. We also take a closer look at several policy and operational issues affecting providers. A McKnight's article examines CMS's interest in expanding dialysis access within sniff communities through potential reimbursement incentives and demonstration projects. Another story explores CMS's growing fraud enforcement authority, including the increasing use of artificial intelligence and analytics to identify potentially problematic providers, while raising important questions about due process and transparency. Finally, we discuss a rare legal victory for a skilled nursing provider after an NLRB judge dismissed a union interference claim, offering important lessons in labor relations, communication practices, and risk management for senior care leaders. As always, we focus on what these developments mean in practice and the key takeaways listeners can apply in their own communities.